Gilead Sciences
Search results
At Regeneron, we've been committed to making a difference in patients' lives for over 30 years. We've done this by following the science. One of the things that's made Regeneron really unique is its willingness to invest in cutting edge technologies.
At Regeneron, we move science to medicine because our world is meant for more. Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need. Explore Regeneron's global presence.
Mar 23, 2021 · FDA recently updated U.S. EUA fact sheets for all authorized monoclonal antibody treatments, indicating that REGEN-COV is the only one to retain potency against key emerging variants. Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to EUA.
Jul 30, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for the investigational COVID-19 antibody cocktail
Jul 11, 2024 · The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation. May 23. Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO. May 20.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life ...
May 4, 2022 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2022 and provided a business update. "Our strong first quarter performance was marked by top- and bottom-line growth, accompanied by R&D progress and continued investment in our pipeline," said Leonard S. Schleifer , M.D., Ph.D ...
